GenVec Stock Price, News & Analysis (NASDAQ:GNVC)

$7.19 -0.02 (-0.28 %)
(As of 12/15/2017 01:13 AM ET)
Previous Close$7.21
Today's Range$7.01 - $7.25
52-Week Range$2.70 - $10.44
Volume12,900 shs
Average Volume259,136 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About GenVec (NASDAQ:GNVC)

GenVec logoGenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company's development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company's lead product candidate is CGF166. The Company's vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.

Receive GNVC News and Ratings via Email

Sign-up to receive the latest news and ratings for GNVC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:GNVC
CUSIPN/A
Phone+1-240-6320740

Debt

Debt-to-Equity RatioN/A
Current Ratio2.10%
Quick Ratio2.10%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($3.67)
Net IncomeN/A
Net Margins-3,748.25%
Return on Equity-648.22%
Return on Assets-271.77%

Miscellaneous

Employees15
Outstanding Shares2,270,000

GenVec (NASDAQ:GNVC) Frequently Asked Questions

What is GenVec's stock symbol?

GenVec trades on the NASDAQ under the ticker symbol "GNVC."

When did GenVec's stock split? How did GenVec's stock split work?

Shares of GenVec reverse split on Thursday, December 1st 2016. The 1-10 reverse split was announced on Wednesday, November 16th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 30th 2016. An investor that had 100 shares of GenVec stock prior to the reverse split would have 10 shares after the split.

How were GenVec's earnings last quarter?

GenVec Inc (NASDAQ:GNVC) released its quarterly earnings results on Friday, November, 4th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.03. The biopharmaceutical company earned $0.17 million during the quarter, compared to analysts' expectations of $0.07 million. GenVec had a negative net margin of 3,748.25% and a negative return on equity of 648.22%. View GenVec's Earnings History.

Where is GenVec's stock going? Where will GenVec's stock price be in 2017?

2 Wall Street analysts have issued 12 month target prices for GenVec's shares. Their predictions range from $7.00 to $7.00. On average, they expect GenVec's stock price to reach $7.00 in the next year. View Analyst Ratings for GenVec.

Who are some of GenVec's key competitors?

Who are GenVec's key executives?

GenVec's management team includes the folowing people:

  • Wayne T. Hockmeyer Ph.D., Independence Chairman of the Board
  • Douglas J. Swirsky, President, Chief Executive Officer, Corporate Secretary, Director
  • William N. Kelley M.D., Independent Director
  • Stefan D. Loren Ph.D., Independent Director
  • Quinterol J. Mallette M.D., Independent Director
  • Michael S. Richman, Independent Director
  • Marc R. Schneebaum, Independent Director

How do I buy GenVec stock?

Shares of GenVec can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GenVec's stock price today?

One share of GenVec stock can currently be purchased for approximately $7.19.

How can I contact GenVec?

GenVec's mailing address is 910 Clopper Rd Ste 220n, GAITHERSBURG, MD 20878-1353, United States. The biopharmaceutical company can be reached via phone at +1-240-6320740.


MarketBeat Community Rating for GenVec (GNVC)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  86 (Vote Outperform)
Underperform Votes:  60 (Vote Underperform)
Total Votes:  146
MarketBeat's community ratings are surveys of what our community members think about GenVec and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

GenVec (NASDAQ:GNVC) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.332.332.332.33
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.33$11.33$11.33$11.33
Price Target Upside: 72.50% upside72.50% upside72.50% upside72.50% upside

GenVec (NASDAQ:GNVC) Consensus Price Target History

Price Target History for GenVec (NASDAQ:GNVC)

GenVec (NASDAQ:GNVC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/25/2017HC WainwrightDowngradeHold$7.00N/AView Rating Details
1/25/2017Rodman & RenshawDowngradeBuy -> Neutral$15.00 -> $7.00N/AView Rating Details
7/26/2016Roth CapitalReiterated RatingBuy$80.00 -> $20.00N/AView Rating Details
(Data available from 12/15/2015 forward)

Earnings

GenVec (NASDAQ:GNVC) Earnings History and Estimates Chart

Earnings by Quarter for GenVec (NASDAQ:GNVC)

GenVec (NASDAQ GNVC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/4/2016Q3 2016($0.08)($0.05)$0.07 million$0.17 millionViewN/AView Earnings Details
8/5/2016Q116($0.10)($0.06)$0.12 million$0.03 millionViewN/AView Earnings Details
5/12/2016Q1 2016($0.09)($0.11)$0.18 million$0.29 millionViewN/AView Earnings Details
3/9/2016Q415($0.08)($0.10)$0.21 million$0.16 millionViewN/AView Earnings Details
11/9/2015Q3 2015($0.11)($0.09)$0.15 million$0.19 millionViewN/AView Earnings Details
8/7/2015Q215($0.10)($0.11)$0.38 million$0.13 millionViewN/AView Earnings Details
5/8/2015Q115($0.06)($0.09)$0.91 million$0.41 millionViewN/AView Earnings Details
3/24/2015Q414$0.08$0.11$3.33 million$3.50 millionViewListenView Earnings Details
11/12/2014Q314($0.09)($0.10)$1.00 million$0.25 millionViewN/AView Earnings Details
8/12/2014Q214($0.15)($0.10)$0.13 millionViewN/AView Earnings Details
5/12/2014Q114$0.04($0.07)$2.00 million$2.10 millionViewN/AView Earnings Details
3/28/2014Q413($0.16)($0.07)$1.52 million$0.15 millionViewListenView Earnings Details
11/12/2013Q313($0.23)$2.10 million$1.60 millionViewN/AView Earnings Details
11/9/2012Q312($0.32)($0.30)$2.90 million$2.13 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

GenVec (NASDAQ:GNVC) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for GenVec (NASDAQ:GNVC)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

GenVec (NASDAQ GNVC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.10%
Institutional Ownership Percentage: 6.22%
Insider Trades by Quarter for GenVec (NASDAQ:GNVC)
Institutional Ownership by Quarter for GenVec (NASDAQ:GNVC)

GenVec (NASDAQ GNVC) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/16/2016Douglas J SwirskyCEOBuy10,000$0.50$5,000.00View SEC Filing  
12/14/2015Douglas J SwirskyCEOBuy5,000$2.00$10,000.00View SEC Filing  
11/16/2015Stefan LorenDirectorBuy4,000$1.93$7,720.00View SEC Filing  
8/11/2015Douglas E BroughInsiderBuy4,600$2.34$10,764.00View SEC Filing  
5/27/2014Ecor1 Capital, LlcMajor ShareholderBuy24,140$2.24$54,073.60View SEC Filing  
3/28/2014Ecor1 Capital, LlcMajor ShareholderBuy122,273$2.55$311,796.15View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

GenVec (NASDAQ GNVC) News Headlines

Source:
DateHeadline
GenVec (GNVC) vs. Its Rivals Financial ReviewGenVec (GNVC) vs. Its Rivals Financial Review
www.americanbankingnews.com - November 27 at 11:24 PM
Aptose Biosciences (APTO) & GenVec (GNVC) Financial SurveyAptose Biosciences (APTO) & GenVec (GNVC) Financial Survey
www.americanbankingnews.com - November 14 at 1:36 PM
GenVec (GNVC) versus CTI BioPharma Corp. (CTIC) Critical ReviewGenVec (GNVC) versus CTI BioPharma Corp. (CTIC) Critical Review
www.americanbankingnews.com - October 24 at 8:50 PM
GenVec, Inc. :GNVC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017GenVec, Inc. :GNVC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
finance.yahoo.com - October 5 at 8:13 AM
Intrexon Integrates Leading Adenoviral Gene Delivery Technology with Completion of GenVec AcquisitionIntrexon Integrates Leading Adenoviral Gene Delivery Technology with Completion of GenVec Acquisition
finance.yahoo.com - October 5 at 8:13 AM
Reviewing Arena Pharmaceuticals (ARNA) and GenVec (GNVC)Reviewing Arena Pharmaceuticals (ARNA) and GenVec (GNVC)
www.americanbankingnews.com - October 4 at 12:24 AM
Head to Head Survey: Organovo Holdings (ONVO) and GenVec (GNVC)Head to Head Survey: Organovo Holdings (ONVO) and GenVec (GNVC)
www.americanbankingnews.com - August 30 at 9:12 AM
Intrexon Integrates Leading Adenoviral Gene Delivery Technology with ...Intrexon Integrates Leading Adenoviral Gene Delivery Technology with ...
www.prnewswire.com - June 17 at 10:55 PM
How These Biotech Stocks are Faring? -- Pluristem Therapeutics, BioLine Rx, GenVec, and Diffusion PharmaHow These Biotech Stocks are Faring? -- Pluristem Therapeutics, BioLine Rx, GenVec, and Diffusion Pharma
www.bizjournals.com - April 28 at 10:35 AM
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against GenVec, Inc.SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against GenVec, Inc.
feeds.benzinga.com - April 17 at 9:21 PM
GENVEC INC Files SEC form 10-K, Annual ReportGENVEC INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 6 at 5:07 PM
WeissLaw LLP: GenVec, Inc. Acquisition May Not Be in the Best Interests of GNVC Shareholders - PR Newswire (press release)WeissLaw LLP: GenVec, Inc. Acquisition May Not Be in the Best Interests of GNVC Shareholders - PR Newswire (press release)
www.prnewswire.com - February 8 at 11:04 PM
Rodman & Renshaw Downgrades GenVec, Inc. (GNVC) to Neutral - StreetInsider.comRodman & Renshaw Downgrades GenVec, Inc. (GNVC) to Neutral - StreetInsider.com
www.streetinsider.com - January 26 at 6:57 PM
Intrexon To Buy GenVec For $7 a Share (XON, GNVC)Intrexon To Buy GenVec For $7 a Share (XON, GNVC)
www.investopedia.com - January 25 at 4:51 PM
Intrexon To Buy GenVec In Stock Deal For $7/ShrIntrexon To Buy GenVec In Stock Deal For $7/Shr
www.investopedia.com - January 25 at 4:51 PM
GenVec Inc. (GNVC) Is Up Sharply After Bought By IntrexonGenVec Inc. (GNVC) Is Up Sharply After Bought By Intrexon
www.rttnews.com - January 24 at 6:14 PM
GENVEC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Rights of SecuritGENVEC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Rights of Securit
biz.yahoo.com - January 24 at 6:14 PM
East Coast biotech company licenses Washington U technologyEast Coast biotech company licenses Washington U technology
www.bizjournals.com - January 9 at 4:18 PM
GenVec Signs Option Agreement for Gene Editing and Cell Targeting Technology from Washington University in St. LouisGenVec Signs Option Agreement for Gene Editing and Cell Targeting Technology from Washington University in St. Louis
us.rd.yahoo.com - January 5 at 6:28 PM
8:12 am GenVec enters into an exclusive option agreement with Washington University in St. Louis to license intellectual property and technology related to gene editing and pulmonary endothelial cell targeting8:12 am GenVec enters into an exclusive option agreement with Washington University in St. Louis to license intellectual property and technology related to gene editing and pulmonary endothelial cell targeting
us.rd.yahoo.com - January 5 at 6:28 PM

SEC Filings

GenVec (NASDAQ:GNVC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

GenVec (NASDAQ:GNVC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

GenVec (NASDAQ GNVC) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.